The oncogenicity of Jun.

abstract：:Bone mineral density (BMD) and biochemical markers of bone metabolism were analyzed in 67 adults with ALL (n = 27), AML (n = 14), MDS (n = 6) and CML (n = 20) before and after allogeneic stem cell transplantation (SCT). Median age was 36 years (17-56). Twenty-six out of 53 patients (49%) had osteopenia and osteoporosi...

journal_title：Leukemia

authors： Massenkeil G,Fiene C,Rosen O,Michael R,Reisinger W,Arnold R

更新日期：2001-11-01 00:00:00

abstract：:All-trans retinoic acid (ATRA) has recently been shown to synergize with the inhibitory effect of interferon alpha (IFN alpha) on the growth of malignant cells isolated from solid tumors. We investigated whether ATRA could potentiate the inhibitory effects of IFN alpha on the proliferation of leukemic progenitors in c...

journal_title：Leukemia

authors： Mahon FX,Chahine H,Barbot C,Pigeonnier V,Jazwiec B,Reiffers J,Ripoche J

更新日期：1997-05-01 00:00:00

abstract：:There is a clear association between the Epstein-Barr virus (EBV) and Hodgkin's disease (HD). EBV is not, however, detectable within the affected tissues of all cases. The proportion of positive cases varies from 15-79% depending on the assay used to detect EBV. The techniques utilised vary not only in sensitivity but...

journal_title：Leukemia

authors： Armstrong AA,Weiss LM,Gallagher A,Jones DB,Krajewski AS,Angus B,Brown G,Jack AS,Wilkins BS,Onions DE

更新日期：1992-09-01 00:00:00

abstract：:Two hundred and forty-four untreated acute myelogenous leukemia (AML) patients with unfavorable karyotypes and 109 others with favorable aneuploid karyotypes were used to evaluate the prognostic significance of having both normal and abnormal metaphases (AN) vs only abnormal metaphases (AA) at AML presentation. The AA...

journal_title：Leukemia

authors： Ghaddar HM,Pierce S,Reed P,Estey EH

更新日期：1995-05-01 00:00:00

abstract：:Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that de...

journal_title：Leukemia

authors： Kampen KR,Ter Elst A,Mahmud H,Scherpen FJ,Diks SH,Peppelenbosch MP,de Haas V,Guryev V,de Bont ES

更新日期：2014-03-01 00:00:00

abstract：:The t(1;19)(q23;p13), a non-random chromosome rearrangement associated with childhood pre-B acute lymphoblastic leukemia (ALL), results at molecular level in the hybrid E2A-PBX1 gene. This gene is expressed in a typical set of fusion transcripts and oncogenic chimeric proteins. However, the occurrence of t(1;19) molec...

journal_title：Leukemia

authors： Privitera E,Luciano A,Ronchetti D,Aricò M,Santostasi T,Basso G,Biondi A

更新日期：1994-04-01 00:00:00

abstract：:Adhesion molecules and stromal cell-derived factor-1 (SDF-1)/CXCR4 signaling play key role in homing and mobilization of hematopoietic progenitor (HPC) and hematopoietic cancer clonogenic cells (HCC). High expression of VLA-4 is required for homing of HPC and HCC, whereas downregulation of these molecules is required ...

journal_title：Leukemia

authors： Gazitt Y

更新日期：2004-01-01 00:00:00

abstract：:We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as well as 4/4 MM and 18/20 AML freshly isolated cases, with a mean IC(5...

journal_title：Leukemia

authors： Golay J,Cuppini L,Leoni F,Micò C,Barbui V,Domenghini M,Lombardi L,Neri A,Barbui AM,Salvi A,Pozzi P,Porro G,Pagani P,Fossati G,Mascagni P,Introna M,Rambaldi A

更新日期：2007-09-01 00:00:00

abstract：:c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

journal_title：Leukemia

authors： Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

更新日期：2013-12-01 00:00:00

abstract：:Recently, it has been clarified that interaction between hematopoietic cells and endothelial cells is important in normal hematopoiesis and leukemogenesis. In this study, we examined the relationship between AML cells and endothelial cells by analyzing the expression profile of angiogenic factors, angiopoietin-1 (Ang-...

journal_title：Leukemia

authors： Watarai M,Miwa H,Shikami M,Sugamura K,Wakabayashi M,Satoh A,Tsuboi K,Imamura A,Mihara H,Katoh Y,Kita K,Nitta M

更新日期：2002-01-01 00:00:00

abstract：:Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the e...

journal_title：Leukemia

authors： Zhao W,Gu YH,Song R,Qu BQ,Xu Q

更新日期：2008-06-01 00:00:00

abstract：:The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in mast cell growth and differentiation. In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated with phosphatidylinositol 3-kinase (P13K) i...

journal_title：Leukemia

authors： Kanakura Y,Furitsu T,Tsujimura T,Butterfield JH,Ashman LK,Ikeda H,Kitayama H,Kanayama Y,Matsuzawa Y,Kitamura Y

更新日期：1994-04-01 00:00:00

abstract：:The study of intraclonal diversification (ID) in immunoglobulin (IG) genes offers valuable insight into the role of ongoing interactions with antigen in lymphomagenesis. We recently showed that ID in the IG heavy chain genes of patients with chronic lymphocytic leukemia (CLL) was generally limited; however, intense ID...

journal_title：Leukemia

authors： Kostareli E,Sutton LA,Hadzidimitriou A,Darzentas N,Kouvatsi A,Tsaftaris A,Anagnostopoulos A,Rosenquist R,Stamatopoulos K

更新日期：2010-07-01 00:00:00

abstract：:Single-colony karyotyping (SCK) and reverse-transcription polymerase chain reaction (RT-PCR) are two increasingly used techniques for the quantification of leukemic colonies generated by chronic myelogenous leukemia (CML) cell fractions purged or selected in vitro. Recently, the existence of Philadelphia (Ph) chromoso...

journal_title：Leukemia

authors： Savoldo B,Sammarelli G,Dotti G,Garau D,Regazzi E,Cilloni D,Tabilio A,Rizzoli V,Carlo-Stella C

更新日期：1998-03-01 00:00:00

abstract：:Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

journal_title：Leukemia

authors： Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

更新日期：2013-12-01 00:00:00

abstract：:Of 240 Japanese children with acute lymphoblastic leukemia (ALL) treated between 1983 and 1990, 75 (31%) had normal diploidy, 47 (20%) hyperdiploidy with more than 50 chromosomes, 18 (8%) hyperdiploidy with 47-50 chromosomes, 77 (32%) pseudodiploidy, 22 (9%) hypodiploidy and one hypotetraploidy in the leukemic cells. ...

journal_title：Leukemia

authors： Kobayashi H,Maseki N,Homma C,Sakurai M,Kaneko Y

更新日期：1994-11-01 00:00:00

abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

journal_title：Leukemia

authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

更新日期：2014-08-01 00:00:00

abstract：:The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

journal_title：Leukemia

authors： Tefferi A,Vardiman JW

更新日期：2008-01-01 00:00:00

abstract：:The karyotype of a boy with acute lymphoblastic leukemia (ALL) presenting with numerical and structural chromosome aberrations as determined by Giemsa-banding was further investigated using chromosome painting (CP). A translocation t(11;18)(q23;q21) was verified by this approach, and gain of chromosome 21 material due...

journal_title：Leukemia

authors： Rieder H,Kolbus U,Koop U,Ludwig WD,Stollmann-Gibbels B,Fonatsch C

更新日期：1993-10-01 00:00:00

abstract：:We performed cytogenetic and molecular analysis of the BCR-ABL rearrangement by polymerase chain reaction (PCR) in 39 consecutive cases of adult acute lymphoblastic leukemia (ALL). Eleven patients had a Philadelphia (Ph) chromosome. Thirteen patients had a BCR-ABL rearrangement, involving minor breakpoint cluster regi...

journal_title：Leukemia

authors： Preudhomme C,Fenaux P,Lal JL,Lepelley P,Sartiaux C,Collyn-d'Hooghe M,Zandecki M,Cosson A,Jouet JP,Kerckaert JP

更新日期：1993-07-01 00:00:00

abstract：:The proto-oncogene c-Jun has been implicated in the control of cell proliferation and differentiation and more recently in the regulation of apoptosis. We have previously reported the involvement of c-Jun in the erythroid differentiation block in murine erythroleukemia (MEL) cells. As reported here, we investigated th...

journal_title：Leukemia

authors： Poindessous-Jazat V,Augery-Bourget Y,Robert-Lézénès J

更新日期：2002-02-01 00:00:00

abstract：:Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

journal_title：Leukemia

authors： Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

更新日期：2012-07-01 00:00:00

abstract：:The occurrence of leukemia in a gene therapy trial for SCID-X1 has highlighted insertional mutagenesis as an adverse effect. Although retroviral integration near the T-cell acute lymphoblastic leukemia (T-ALL) oncogene LIM-only protein 2 (LMO2) appears to be a common event, it is unclear why LMO2 was preferentially ta...

journal_title：Leukemia

authors： Pike-Overzet K,de Ridder D,Weerkamp F,Baert MR,Verstegen MM,Brugman MH,Howe SJ,Reinders MJ,Thrasher AJ,Wagemaker G,van Dongen JJ,Staal FJ

更新日期：2007-04-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

journal_title：Leukemia

authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

更新日期：2014-10-01 00:00:00

abstract：:Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern ...

journal_title：Leukemia

authors： De Luca K,Frances-Duvert V,Asensio MJ,Ihsani R,Debien E,Taillardet M,Verhoeyen E,Bella C,Lantheaume S,Genestier L,Defrance T

更新日期：2009-11-01 00:00:00

abstract：:The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among...

journal_title：Leukemia

authors： Kalina T,Flores-Montero J,van der Velden VH,Martin-Ayuso M,Böttcher S,Ritgen M,Almeida J,Lhermitte L,Asnafi V,Mendonça A,de Tute R,Cullen M,Sedek L,Vidriales MB,Pérez JJ,te Marvelde JG,Mejstrikova E,Hrusak O,Szczepańs

更新日期：2012-09-01 00:00:00

abstract：:To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

journal_title：Leukemia

authors： Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

更新日期：2006-08-01 00:00:00

abstract：:Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

journal_title：Leukemia

authors： Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:This report summarizes recent findings in the field of basic and translational apoptosis research which were presented at the 1st Conference on 'Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention' organized by the European School of Hematology and the University of Texas MD Anderson Cancer Cent...

journal_title：Leukemia

authors： Daniel PT

更新日期：2000-12-01 00:00:00

abstract：:Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

journal_title：Leukemia

authors： Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

更新日期：2018-05-01 00:00:00